Piśmiennictwo:

1. Deeks JJ, Smith LA, Bradley MD. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. BMJ 2002;325:619-29.

2. Wallace JL, McKnight W, Reuter BK, Vergnolle N. NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology 2000;119:706-14.

3. Bresalier RS, Sandler RS, Quan H, et al., for the Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352;1092-102.

4. Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005;352:1081-91.

5. Solomon SD, Pfeffer MA, McMurray JJ, et al. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation 2006;114:1028-35.

6. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001;954:954-9.

7. Bombardier C, Laine L, Reicin A, et al, for the VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520-8.

8. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284:1247-55.

9. Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 2006;116:4-15.

10. Johanson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Am Intern Med 1994;121:289-300.

11. Amer M, Bead VR, Bathon J, et al. Use of nonsteroidal anti-inflammatory drugs in patients with cardiovascular disease – a cautionary tale. Cardiol Rev 2010;18(4):204-12.

12. Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Int Med 1993;153:477-84.

13. Clive DM, Stoff JS. Renal syndromes associated with nonsteroidal anti-inflammatory drugs. N Engl J Med 1984;310:563-72.

14. Peplov PV. Properties and actions of non-steroidal anti-inflammatory drugs, including their effects on prostaglandin and macromolecular synthesis. Prostaglandins Leukot Essent Fatty Acid 1988;33:239-52.

15. Whelton A, Hamilton CW. Nonsteroidal anti-inflammatory drugs: effects on kidney function. J Clin Pharmacol 1991;31:588-98.

16. Qi Z, Hao CM, Langenbach RI, et al. Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II. J Clin Invest 2002;110:61-9.

17. Smyth EM, Grosser T, FitzGerald GA. Lipid-derived autacoids: eicosanoids and platelet-activating factor. In: Brunton LL, Chabner BA, Knollmann BC (editors). Goodman and Gilman’s The pharmacological basis of therapeutics. New York: McGraw-Hill Medical, 2011:937-57.

18. Snowden S, Nelson R. The effects of nonsteroidal anti-inflammatory drugs on blood pressure in hypertensive patients. Cardiol Rev 2011;19:184-91.

19. Whelton A, White WB, Bello AE, Puma JA, Fort JG, SUCCESS-VII Investigators. Effects of celecoxib and rofecoxib on blood pressure and edema patients ≥65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol 2002;90:959-63.

20. Siyam F, Brietzke SA, Sowers JR. Resistant hypertension in office practice: a clinical approach. Hosp Pract (Minneap) 2010:38:90-7.

21. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur Heart J 2008;29:2388-442.

22. Cheng Y, Austin SC, Rocca B, et al. Role of prostacyclin in the cardiovascular response to thromboxane A@2. Science 2002;296:539-41.

23. Egan K, Smyth E, Fries S, et al. Prostacyclin confers atheroprotection on female mice. Science 2004;306:1954-7.

24. Kobayashi T, Tahara Y, Matsumoto M, et al. Roles of thromboxane A(2) and prostacyclin in the development of atherosclerosis in apoE-deficient mice. J Clin Invest 2004;114:784-94.

25. Cheng Y, Wang M, Yu Y, et al. Cyclooxygenases, mPGES-1 and cardiovascular function. J Clin Invest 2006;116:1391-9.

26. Arehart E, Stitham J, Asselbergs FW, et al. Acceleration of cardiovascular disease by a dysfunctional prostacyclin receptor mutation: potential implications for cyclooxygenase-2 inhibition. Circ Res 2008;102:986-93.

27. McAdam BF, Catella-Lawson F, Mardini IA, et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A 1999;96:272-7.

28. Catella-Lawson F, McAdam B, Morrison BW, et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther 1999;289:735-41.

29. Belton O, Byrne D, Kearney D, et al. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation 2000;102:840-5.

30. FDA 2004: Public Health Advisory: Non-Steroidal Anti-Inflammatory Drug Products (NSAIDS). http://www.fda.gov/Drugs/DrugsSafety/PostmarketDrugSafetyInformationforPatientsandProviders

31. EMA 2005a: European Medicines Agency concludes action on COX-2 inhibitors. http://www.ema.europa.eu/news_and_events/news

32. FDA 2005a: Analysis and recommendations for agency action regarding non-steroidal anti-inflammatory drugs and cardiovascular risk. J Pain Palliat Care Pharmacother 2005;19:83-97.

33. FDA 2005b: COX-2 Selective (includes Bextra, Celebrex, and Vioxx) and Non-Selective Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). http://www.fda.gov/Drugs/DrugsSafety/PostmarketDrugSafetyInformationforPatientsandProviders

34. EMA 2005b: Press release on cardiovascular safety on non-selective NSAIDS. http://www.ema.europa.eu/news_and_events/news

35. EMA 2006: European Medicines Agency update on review of non-selective NSAIDs. Press release. http://www.ema.europa.eu/news_and_events/news

36. Kearney PM, Baigent C, Godwin J, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomized trials. BMJ 2006;332:1302-8.

37. Gislason GH, Jacobsen S, Rasmussen JN, et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal anti-inflammatory drugs after acute myocardial infarction. Circulation 2006;113:2906-13.

38. Steg PG, James SK, Atar D et al. ESC guidelines for the management of acute myocardial infarctionin patients presenting with ST-segment elevation. Eur Heart J 2012; 33: 2569-2619.

39. Hamm CW, Bassand JP, Agewall S, et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2011;32:2999-3054.

40. Schjerning Olsen AM, Fosbol EL, Lindhardsen J, et al. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction. Circulation 2011;123:2226-35.

41. EMA 2011: European Medicines Agency starts new review of cardiovascular risks of non-selective NSAIDs. Press release. http://www.ema.europa.eu/news_and_events/news

42. Weil J, Colin-Jones D, Langman M, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 1995;310:827-30.

43. Yeomans ND, Lanas AI, Talley NJ, et al. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther 2005;22:795-801.

44. Bhat DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents. Circulation 2008;118:1894-909.

45. Gladding PA, Webster MWI, Farrell HB, et al. The antiplatelet effect of six non-steroidal anti-inflammatory drugs and their pharmacodynamic interaction with aspirin in healthy volunteers. Am J Cardiol 2008;101:1060-3.

46. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and antiplatelet effect of aspirin. N Engl J Med 2001;345:1809-17.

47. Wilner KD, Rushing M, Walden C, et al. Celecoxib does not affect the antiplatelet activity of aspirin in healthy volunteers. J Clin Pharmacol 2002;42:1027-30.

48. Antman EM, Bennett JS, Daugherty A, et al. Use of nonsteroidal anti-inflammatory drugs: an update for clinicians. A scientific statement from American Heart Association. Circulation 2007;115:1634-42.

49. Taubert KA. Can patients with cardiovascular disease take nonsteroidal anti-inflammatory drugs? Circulation 2008;117:e322-4.

50. Whelton A, Gibofsky A. Minimizing cardiovascular complications during the treatment of osteoarthritis. Am J Ther 2011;18:466-7.